Analysts’ Viewpoint on Market Scenario
Increase in prevalence of genetic disorders, growth in demand for personalized medicines, and development of more advanced gene editing technologies are some of the major factors fueling the gene vector industry size. Furthermore, rise in demand for gene therapies and increase in investment in gene therapy research and development activities are also anticipated to aid in market development.
Improvement in healthcare infrastructure across various developing economies along with increased government funding and support for the development of new types of gene vectors, such as viral and non-viral vectors, are likely to positively affect the global industry dynamics in the near future. However, the high cost of gene therapies and the challenges associated with the regulatory approval of gene therapies may limit the gene vector market growth to some extent.
A gene vector is a DNA molecule used to deliver genetic material into cells. It is used to introduce new genetic material into cells in order to study gene function, express a protein, or alter the characteristics of a cell. Gene vectors are commonly used in molecular biology and biotechnology research; they have also been used in the development of gene therapies.
The global market is expected to grow significantly during the forecast period, owing to the development of new gene editing technologies. Additionally, increase in focus on research and development in the field of gene therapy and rapid adoption of gene therapies in clinical practice are also expected to propel the gene vector market size in the near future.
Request a sample to get extensive insights into the Gene Vector Market
Gene therapy involves the use of gene vectors to introduce functional genes into cells to treat or prevent diseases, and it has gained significant traction in the last few years. Increase in awareness about the benefits of gene therapy is anticipated to boost the gene vector market demand in the next few years.
Gene therapy has the potential to treat a wide range of diseases, including genetic disorders, cancers, and infectious diseases. It can also offer a one-time treatment for diseases that currently require lifelong management, such as hemophilia and cystic fibrosis. Moreover, increase in prevalence of genetic diseases, such as cystic fibrosis and sickle cell anemia, is also driving market growth. Rapid development of new and improved gene vector products is further contributing to the gene vector market statistics.
Technological advancements have led to the development of new gene delivery methods, such as lipid nanoparticles and polymeric nanoparticles, which have improved the efficiency and safety of gene vectors. According to the gene vector market analysis, improvement in gene editing technologies, such as CRISPR/Cas9, and the development of new vector types are key factors driving market progress.
Introduction of new production techniques and automation have enabled the large-scale production of gene vectors as well as the development of new and improved manufacturing processes for gene vectors.
Request a custom report on Gene Vector Market
Gene therapy is a promising approach to treat genetic disorders and consequently, companies and researchers are investing significantly in the development of new gene vectors for the treatment of various diseases.
Increase in applications of genetic engineering, rise in importance of biotechnology and precision medicine, and increase in government and private funding for gene therapy research are some of the factors further contributing to market expansion.
Based on vector type, the global market segmentation comprises lentivirus, adenovirus, adeno-associated virus (AAV), plasmid DNA, and others. The plasmid DNA segment is expected to dominate the global market in the next few years, owing to its unique properties. Plasmid DNA is relatively easy to work with, as it can be purified from bacteria using simple techniques, and manipulated using standard molecular biology methods such as restriction enzyme digestion and ligation.
Moreover, it has the ability to be used to clone and express a wide range of genes in various organisms, including bacteria, yeast, and mammalian cells. Plasmid DNA vectors are widely used in the gene therapy research field. Therefore, the segment is anticipated to dominate the market during forecast period.
Regional analysis of the global gene vector market forecast reveals that North America is likely to account for a dominant market share during the forecast period. Improvement in research and development infrastructure in the U.S. and Canada; well-established biotech and pharmaceutical industries in the region, and presence of a large number of academic research institutions that are active in the field of molecular biology and genetics are major factors fueling gene vector market development in North America.
Rise in prevalence of genetic diseases along with, high incidence of genetic disorders, such as thalassemia, sickle cell anemia, and beta-thalassemia, is driving the demand for gene therapy products and services in Asia Pacific. Several countries in Asia Pacific are investing heavily in R&D, and have been providing funding for R&D activities related to gene therapy. Therefore, the Asia Pacific market is expected to expand at a notable CAGR during the forecast period.
The market in Asia Pacific is estimated to increase during the forecast period, also due to the rise in incidence of genetic disorders, government funding and support, development of new gene vector delivery systems, high prevalence of cancer, and increase in number of clinical trials investigating the use of gene therapy and gene vectors.
This report provides profiles of leading players operating in the global market. Prominent gene vector market players include Lonza, Merck KGaA, Oxford Biomedica, CGT Catapult, Charles River Laboratories, uniQure N.V., FUJIFILM Diosynth Biotechnologies, and Spark Therapeutics, Inc. Increase in mergers & acquisitions, strategic collaborations, and new product launches is expected to drive the global market during the forecast period.
Key players have been profiled in the global gene vector market report based on parameters such as company overview, financial overview, product portfolio, business strategies, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 991.1 Mn |
|
Market Forecast Value in 2031 |
More than US$ 3.4 Bn |
|
Growth Rate (CAGR) 2022-2031 |
12.6% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Mn/Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
It market was valued at US$ 991.1 Mn in 2021.
It is projected to reach more than US$ 3.4 Bn by 2031.
The CAGR is anticipated to be 12.6% from 2022 to 2031.
The plasmid DNA vector type segment accounted for the largest share of more than 35.0% in 2021.
North America is expected to account for significant share during the forecast period.
Lonza, Merck KGaA, Oxford Biomedica, CGT Catapult, Charles River Laboratories, uniQure N.V., FUJIFILM Diosynth Biotechnologies, Spark Therapeutics, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Gene Vector Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Gene Vector Market Analysis and Forecasts, 2017 - 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Technological Advancements
5.2. Major Research Institutes Involved
5.3. Disease Prevalence & Incidence Rate globally with key countries
5.4. COVID-19 Pandemic Impact on Industry
6. Global Gene Vector Market Analysis and Forecast, by Vector Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Vector Type, 2017 - 2031
6.3.1. Lentivirus
6.3.2. Adenovirus
6.3.3. Adeno-associated Virus (AAV)
6.3.4. Plasmid DNA
6.3.5. Others
6.4. Market Attractiveness, by Vector Type
7. Global Gene Vector Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017 - 2031
7.3.1. Gene Therapy
7.3.2. Vaccinology
7.3.3. Others
7.4. Market Attractiveness, by Application
8. Global Gene Vector Market Analysis and Forecast, by Disease
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Disease, 2017 - 2031
8.3.1. Genetic Disorder
8.3.2. Cancer
8.3.3. Infectious Disease
8.3.4. Others
8.4. Market Attractiveness, by Disease
9. Global Gene Vector Market Analysis and Forecast, by End-user
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by End-user, 2017 - 2031
9.3.1. Scientific Research
9.3.2. CRO
9.3.3. CDMO
9.3.4. Others (Pharmaceutical, Biotechnology Companies)
9.4. Market Attractiveness, by End-user
10. Global Gene Vector Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Country/Region
11. North America Gene Vector Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Vector Type, 2017 - 2031
11.2.1. Lentivirus
11.2.2. Adenovirus
11.2.3. Adeno-associated Virus (AAV)
11.2.4. Plasmid DNA
11.2.5. Others
11.3. Market Value Forecast, by Application, 2017 - 2031
11.3.1. Gene Therapy
11.3.2. Vaccinology
11.3.3. Others
11.4. Market Value Forecast, by Disease, 2017 - 2031
11.4.1. Genetic Disorder
11.4.2. Cancer
11.4.3. Infectious Disease
11.4.4. Others
11.5. Market Value Forecast, by End-user, 2017 - 2031
11.5.1. Scientific Research
11.5.2. CRO
11.5.3. CDMO
11.5.4. Others (Pharmaceutical, Biotechnology Companies)
11.6. Market Value Forecast, by Country, 2017 - 2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Vector Type
11.7.2. By Application
11.7.3. By Disease
11.7.4. By End-user
11.7.5. By Country
12. Europe Gene Vector Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Vector Type, 2017 - 2031
12.2.1. Lentivirus
12.2.2. Adenovirus
12.2.3. Adeno-associated Virus (AAV)
12.2.4. Plasmid DNA
12.2.5. Others
12.3. Market Value Forecast, by Application, 2017 - 2031
12.3.1. Gene Therapy
12.3.2. Vaccinology
12.3.3. Others
12.4. Market Value Forecast, by Disease, 2017 - 2031
12.4.1. Genetic Disorder
12.4.2. Cancer
12.4.3. Infectious Disease
12.4.4. Others
12.5. Market Value Forecast, by End-user, 2017 - 2031
12.5.1. Scientific Research
12.5.2. CRO
12.5.3. CDMO
12.5.4. Others (Pharmaceutical, Biotechnology Companies)
12.6. Market Value Forecast, by Country, 2017 - 2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Vector Type
12.7.2. By Application
12.7.3. By Disease
12.7.4. By End-user
12.7.5. By Country
13. Asia Pacific Gene Vector Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Vector Type, 2017 - 2031
13.2.1. Lentivirus
13.2.2. Adenovirus
13.2.3. Adeno-associated Virus (AAV)
13.2.4. Plasmid DNA
13.2.5. Others
13.3. Market Value Forecast, by Application, 2017 - 2031
13.3.1. Gene Therapy
13.3.2. Vaccinology
13.3.3. Others
13.4. Market Value Forecast, by Disease, 2017 - 2031
13.4.1. Genetic Disorder
13.4.2. Cancer
13.4.3. Infectious Disease
13.4.4. Others
13.5. Market Value Forecast, by End-user, 2017 - 2031
13.5.1. Scientific Research
13.5.2. CRO
13.5.3. CDMO
13.5.4. Others (Pharmaceutical, Biotechnology Companies)
13.6. Market Value Forecast, by Country, 2017 - 2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Vector Type
13.7.2. By Application
13.7.3. By Disease
13.7.4. By End-user
13.7.5. By Country
14. Latin America Gene Vector Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Vector Type, 2017 - 2031
14.2.1. Lentivirus
14.2.2. Adenovirus
14.2.3. Adeno-associated Virus (AAV)
14.2.4. Plasmid DNA
14.2.5. Others
14.3. Market Value Forecast, by Application, 2017 - 2031
14.3.1. Gene Therapy
14.3.2. Vaccinology
14.3.3. Others
14.4. Market Value Forecast, by Disease, 2017 - 2031
14.4.1. Genetic Disorder
14.4.2. Cancer
14.4.3. Infectious Disease
14.4.4. Others
14.5. Market Value Forecast, by End-user, 2017 - 2031
14.5.1. Scientific Research
14.5.2. CRO
14.5.3. CDMO
14.5.4. Others (Pharmaceutical, Biotechnology Companies)
14.6. Market Value Forecast, by Country, 2017 - 2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Vector Type
14.7.2. By Application
14.7.3. By Disease
14.7.4. By End-user
14.7.5. By Country
15. Middle East & Africa Gene Vector Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Vector Type, 2017 - 2031
15.2.1. Lentivirus
15.2.2. Adenovirus
15.2.3. Adeno-associated Virus (AAV)
15.2.4. Plasmid DNA
15.2.5. Others
15.3. Market Value Forecast, by Application, 2017 - 2031
15.3.1. Gene Therapy
15.3.2. Vaccinology
15.3.3. Others
15.4. Market Value Forecast, by Disease, 2017 - 2031
15.4.1. Genetic Disorder
15.4.2. Cancer
15.4.3. Infectious Disease
15.4.4. Others
15.5. Market Value Forecast, by End-user, 2017 - 2031
15.5.1. Scientific Research
15.5.2. CRO
15.5.3. CDMO
15.5.4. Others (Pharmaceutical, Biotechnology Companies)
15.6. Market Value Forecast, by Country, 2017 - 2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Vector Type
15.7.2. By Application
15.7.3. By Disease
15.7.4. By End-user
15.7.5. By Country
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of companies)
16.2. Market Share Analysis By Company (2021)
16.3. Company Profiles
16.3.1. Lonza
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Merck KGaA
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Oxford Biomedica
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. CGT Catapult
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Charles River Laboratories
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. uniQure N.V.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. FUJIFILM Diosynth Biotechnologies
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Spark Therapeutics, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Other Prominent Players
List of Tables
Table 01: Global Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031
Table 02: Global Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 03: Global Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 04: Global Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 05: Global Gene Vector Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031
Table 07: North America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 08: North America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 09: North America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 10: North America Gene Vector Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 11: Europe Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031
Table 12: Europe Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 13: Europe Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 14: Europe Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 15: Europe Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031
Table 17: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 19: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 20: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 21: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031
Table 22: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 23: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 24: Latin America Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 25: Latin America Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Vector Type, 2017–2031
Table 27: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 28: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Disease, 2017–2031
Table 29: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 30: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
List of Figures
Figure 01: Global Gene Vector Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
Figure 03: Global Gene Vector Market Attractiveness Analysis, by Vector Type, 2022–2031
Figure 04: Global Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
Figure 05: Global Gene Vector Market Attractiveness Analysis, by Application, 2022–2031
Figure 06: Global Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
Figure 07: Global Gene Vector Market Attractiveness Analysis, by Disease, 2022–2031
Figure 08: Global Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
Figure 09: Global Gene Vector Market Attractiveness Analysis, by End-user, 2022–2031
Figure 10: Global Gene Vector Market Value Share Analysis, by Region, 2021 and 2031
Figure 11: Global Gene Vector Market Attractiveness Analysis, by Region, 2022–2031
Figure 12: North America Gene Vector Market Value (US$ Mn) Forecast, 2017–2031
Figure 13: North America Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
Figure 14: North America Gene Vector Market Attractiveness Analysis, by Vector Type, 2022–2031
Figure 15: North America Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
Figure 16: North America Gene Vector Market Attractiveness Analysis, by Application, 2022–2031
Figure 17: North America Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
Figure 18: North America Gene Vector Market Attractiveness Analysis, by Disease, 2022–2031
Figure 19: North America Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
Figure 20: North America Gene Vector Market Attractiveness Analysis, by End-user, 2022–2031
Figure 21: North America Gene Vector Market Value Share Analysis, by Country, 2021 and 2031
Figure 22: North America Gene Vector Market Attractiveness Analysis, by Country, 2022–2031
Figure 23: Europe Gene Vector Market Value (US$ Mn) Forecast, 2017–2031
Figure 24: Europe Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
Figure 25: Europe Gene Vector Market Attractiveness Analysis, by Vector Type, 2022–2031
Figure 26: Europe Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
Figure 27: Europe Gene Vector Market Attractiveness Analysis, by Application, 2022–2031
Figure 28: Europe Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
Figure 29: Europe Gene Vector Market Attractiveness Analysis, by Disease, 2022–2031
Figure 30: Europe Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
Figure 31: Europe Gene Vector Market Attractiveness Analysis, by End-user, 2022–2031
Figure 32: Europe Gene Vector Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 33: Europe Gene Vector Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 34: Asia Pacific Gene Vector Market Value (US$ Mn) Forecast, 2017–2031
Figure 35: Asia Pacific Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
Figure 36: Asia Pacific Gene Vector Market Attractiveness Analysis, by Vector Type, 2022–2031
Figure 37: Asia Pacific Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
Figure 38: Asia Pacific Gene Vector Market Attractiveness Analysis, by Application, 2022–2031
Figure 39: Asia Pacific Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
Figure 40: Asia Pacific Gene Vector Market Attractiveness Analysis, by Disease, 2022–2031
Figure 41: Asia Pacific Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
Figure 42: Asia Pacific Gene Vector Market Attractiveness Analysis, by End-user, 2022–2031
Figure 43: Asia Pacific Gene Vector Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 44: Asia Pacific Gene Vector Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 45: Latin America Gene Vector Market Value (US$ Mn) Forecast, 2017–2031
Figure 46: Latin America Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
Figure 47: Latin America Gene Vector Market Attractiveness Analysis, by Vector Type, 2022–2031
Figure 48: Latin America Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
Figure 49: Latin America Gene Vector Market Attractiveness Analysis, by Application, 2022–2031
Figure 50: Latin America Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
Figure 51: Latin America Gene Vector Market Attractiveness Analysis, by Disease, 2022–2031
Figure 52: Latin America Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
Figure 53: Latin America Gene Vector Market Attractiveness Analysis, by End-user, 2022–2031
Figure 54: Latin America Gene Vector Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 55: Latin America Gene Vector Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 56: Middle East & Africa Gene Vector Market Value (US$ Mn) Forecast, 2017–2031
Figure 57: Middle East & Africa Gene Vector Market Value Share Analysis, by Vector Type, 2021 and 2031
Figure 58: Middle East & Africa Gene Vector Market Attractiveness Analysis, by Vector Type, 2022–2031
Figure 59: Middle East & Africa Gene Vector Market Value Share Analysis, by Application, 2021 and 2031
Figure 60: Middle East & Africa Gene Vector Market Attractiveness Analysis, by Application, 2022–2031
Figure 61: Middle East & Africa Gene Vector Market Value Share Analysis, by Disease, 2021 and 2031
Figure 62: Middle East & Africa Gene Vector Market Attractiveness Analysis, by Disease, 2022–2031
Figure 63: Middle East & Africa Gene Vector Market Value Share Analysis, by End-user, 2021 and 2031
Figure 64: Middle East & Africa Gene Vector Market Attractiveness Analysis, by End-user, 2022–2031
Figure 65: Middle East & Africa Gene Vector Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
Figure 66: Middle East & Africa Gene Vector Market Attractiveness Analysis, by Country/Sub-region, 2022–2031
Figure 67: Global Gene Vector Market Share Analysis, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Gene Vector Market
*86 figures and 60 tables includes